Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: Independent validation of the p95HER2 clinical cutoff

Clinical Cancer Research

Volumn 20, Issue 10, 2014, Pages 2805-2813

  Duchnowska, Renata ^a   Sperinde, Jeff ^k   Chenna, Ahmed ^k   Haddad, Mojgan ^k   Paquet, Agnes ^k   Lie, Yolanda ^k   Weidler, Jodi M ^k   Huang, Weidong ^k   Winslow, John ^k   Jankowski, Tomasz ^b   Czartoryska Arlukowicz, Bogumita ^c   Wysocki, Piotr J ^d   Foszczynska Ktoda, Matgorzata ^e   Radecka, Barbara ^f   Litwiniuk, Maria M ^d   Zok, Jolanta ^g   Wisniewski, Michat ^h   Zuziak, Dorota ⁱ   Biernat, Wojciech ^j   Jassem, Jacek ^j  

^a Military Institute OfMedicine   (United States)

^b Lublin Oncology Center   (United States)

^c Biatystok Oncology Center   (Poland)

^d GREATER POLAND CANCER CENTER   (Poland)

^e West Pomeranian Oncology Centre   (Poland)

^f Opole Oncology Center   (Poland)

^g Department of Oncology   (Poland)

^h Regional Oncology Centre Bydgoszcz   (Poland)

ⁱ Beskidy Oncological Center   (Poland)

^j MEDICAL UNIVERSITY OF GDANSK   (Poland)

^k MONOGRAM BIOSCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; HORMONE RECEPTOR; P95 PROTEIN; PROGESTERONE RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BREAST METASTASIS; CANCER GRADING; CANCER PATIENT; CONTROLLED STUDY; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT DURATION; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84901044363     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2782     Document Type: Article

References (19)

1. Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ, et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 1998;58:5123-9.
2. Saez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006;12:424-31.
3. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007;99:628-38.
4. Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, Ferrer-Ramon C, et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol Cell Biol 2009;29:3319-31.
5. Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernado Morales C, et al. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. Cancer Res 2013;73:450-8.
6. Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, et al. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab- treated breast cancer patients. Clin Cancer Res 2010;16: 4226-35.
7. Parra-Palau JL, Pedersen K, Peg V, Scaltriti M, Angelini PD, Escorihuela M, et al. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers. Cancer Res 2010;70:8537-46.
8. Arribas J, Baselga J, Pedersen K, Parra-Palau JL. p95HER2 and breast cancer. Cancer Res 2011;71:1515-9.
9. Arribas J, Parra-Palau JL, Pedersen K. HER2 fragmentation and breast cancer stratification. Clin Cancer Res 2010;16:4071-3.
10. Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, et al. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity- based assay. Am J Clin Pathol 2010;134:303-11.
11. Larson JS, Goodman LJ, Tan Y, Defazio-Eli L, Paquet AC, Cook JW, et al. Analytical validation of a highly quantitative, wensitive, qccurate, and reproducible assay (HERmark) for the measurement of HER2 total protein and HER2 homodimers in FFPE breast cancer tumor specimens. Pathol Res Int 2010;2010:814176.
12. Lipton A, Kostler WJ, Leitzel K, Ali SM, Sperinde J, Weidler J, et al. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 2010;116:5168-78.
13. Gianni L, Bianchini G, Kiermaier A, Bianchi G, Im YH, Pienkowski T, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analyses of a 4-Arm randomized phase II Study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC). Cancer Res 2011;71: S5-1.
14. Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini PD, et al. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 2010;16:2688-95.
15. Duchnowska R, Sperinde J, Chenna A, Huang W, Weidler JM, Winslow J, et al. Quantitative p95HER2 levels in primary breast cancers and in matched brain metastases. Cancer Res 2013;73(24 Suppl): Abstract nr P6-11-07.
16. Loibl S, Bruey J, Von Minckwitz G, Huober JB, Press MF, Darb- Esfahani S, et al. Validation of p95 as a predictive marker for trastuzumab- based therapy in primary HER2-positive breast cancer: a translational investigation from the neoadjuvant GeparQuattro study. J Clin Oncol 2011;29(15 suppl):530.
17. Denkert C, Huober J, Loibl S, Prinzler J, Kronenwett R, Darb-Esfahani S, et al. HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Res 2013;15:R11.
18. Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Serra V, Parra JL, et al. High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial. Cancer Res 2013;73(24 Suppl): Abstract nr P1-08-42.
19. Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-1804.